3/5
02:30 pm
rvmd
This One Data Readout Could Make Or Break Revolution Medicines [Seeking Alpha]
Low
Report
This One Data Readout Could Make Or Break Revolution Medicines [Seeking Alpha]
3/3
11:57 am
rvmd
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Low
Report
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/2
04:10 am
rvmd
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs [Yahoo! Finance]
Low
Report
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs [Yahoo! Finance]
2/27
08:44 am
rvmd
Revolution Medicines (RVMD) is now covered by UBS Group AG. They set a "buy" rating and a $145.00 price target on the stock.
Low
Report
Revolution Medicines (RVMD) is now covered by UBS Group AG. They set a "buy" rating and a $145.00 price target on the stock.
2/27
12:00 am
rvmd
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here's Why [Yahoo! Finance]
Low
Report
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here's Why [Yahoo! Finance]
2/26
11:52 am
rvmd
Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $100.00 to $144.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Wells Fargo & Company from $100.00 to $144.00. They now have an "overweight" rating on the stock.
2/26
11:52 am
rvmd
Revolution Medicines (RVMD) had its price target raised by Piper Sandler from $75.00 to $120.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (RVMD) had its price target raised by Piper Sandler from $75.00 to $120.00. They now have an "overweight" rating on the stock.
2/26
08:20 am
rvmd
Revolution Medicines (RVMD) had its price target lowered by Needham & Company LLC from $150.00 to $145.00. They now have a "buy" rating on the stock.
Medium
Report
Revolution Medicines (RVMD) had its price target lowered by Needham & Company LLC from $150.00 to $145.00. They now have a "buy" rating on the stock.
2/26
08:17 am
rvmd
Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment? [Yahoo! Finance]
Medium
Report
Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment? [Yahoo! Finance]
2/26
06:28 am
rvmd
Revolution Medicines (RVMD) was upgraded by Evercore Inc to "strong-buy".
Medium
Report
Revolution Medicines (RVMD) was upgraded by Evercore Inc to "strong-buy".
2/26
12:42 am
rvmd
Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
Medium
Report
Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]
2/25
06:41 pm
rvmd
Revolution Medicines (RVMD) Earnings Transcript [Yahoo! Finance]
Low
Report
Revolution Medicines (RVMD) Earnings Transcript [Yahoo! Finance]
2/25
04:02 pm
rvmd
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Low
Report
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
2/24
04:25 pm
rvmd
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
04:05 pm
rvmd
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
Low
Report
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
2/24
12:42 pm
rvmd
Is Revolution Medicines (RVMD) Share Price Lagging Behind Its Long Term Surge? [Yahoo! Finance]
Low
Report
Is Revolution Medicines (RVMD) Share Price Lagging Behind Its Long Term Surge? [Yahoo! Finance]
2/24
01:36 am
rvmd
JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout [Yahoo! Finance]
Low
Report
JPMorgan Signals High Conviction Ahead of Revolution Medicines (RVMD) Readout [Yahoo! Finance]
2/18
04:17 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 [Yahoo! Finance]
Low
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026 [Yahoo! Finance]
2/18
04:05 pm
rvmd
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Low
Report
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
2/17
08:42 am
rvmd
Revolution Medicines (NASDAQ:RVMD) had its "overweight" rating reaffirmed by analysts at Benchmark Co..
Medium
Report
Revolution Medicines (NASDAQ:RVMD) had its "overweight" rating reaffirmed by analysts at Benchmark Co..
2/11
11:03 am
rvmd
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Medium
Report
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
2/4
04:05 pm
rvmd
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Low
Report
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
2/3
12:51 pm
rvmd
MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]
Low
Report
MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]
2/2
01:32 pm
rvmd
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.
Low
Report
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.
1/29
08:00 am
rvmd
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
Low
Report
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor